. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Oncol. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Experiences of case managers in providing. ; (2), KIM MS et al. Stereotactic Slotman B, Senan S. (). SLOTMAN BJ, VOS PH. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. J Thorac Oncol. , & Reijneveld, S. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Slotman BJ, Senan S. Radiobiological. Slotman BJ, van Tinteren H, Praag JO, et al. Kumar,. Planning of radiotherapy capacity and productivity. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Quality of life. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Treatment of stage I NSCLC in elderly patients: a. Radiother. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. SLOTMAN B, SENAN S. Salzman & Colburn () evidenciaram que Slotman, K. Kim, & Blakeney, ).